Working… Menu

GnRH for Luteal Support in IVF/ICSI/FET Cycles

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02357654
Recruitment Status : Recruiting
First Posted : February 6, 2015
Last Update Posted : April 28, 2021
Information provided by (Responsible Party):
University Reproductive Associates

Brief Summary:
During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

Condition or disease Intervention/treatment Phase
Infertility Drug: GnRH Drug: placebo Phase 4

Detailed Description:
see above

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: GnRH for Luteal Support in IVF/ICSI/FET Cycles
Study Start Date : November 2015
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2022

Arm Intervention/treatment
Experimental: GnRH agonist Drug: GnRH
single shot of GnRH agonist

Placebo Comparator: Placebo Drug: placebo

Primary Outcome Measures :
  1. Live birth per transfer [ Time Frame: 9 months ]

Secondary Outcome Measures :
  1. implantation rates [ Time Frame: 4 weeks ]
  2. clinical pregnancy [ Time Frame: 4 weeks ]
  3. rates of OHSS [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.

Exclusion Criteria:

  • day 3 transfers

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02357654

Layout table for location contacts
Contact: Peter G McGovern, MD 201-288-6330

Layout table for location information
United States, New Jersey
University Reproductive Associates Recruiting
Hasbrouck Heights, New Jersey, United States, 07604
Principal Investigator: Peter G. McGovern, MD         
Sponsors and Collaborators
University Reproductive Associates
Layout table for investigator information
Principal Investigator: Peter G McGovern, MD Rutgers University
Layout table for additonal information
Responsible Party: University Reproductive Associates Identifier: NCT02357654    
Other Study ID Numbers: PRO20140001128
First Posted: February 6, 2015    Key Record Dates
Last Update Posted: April 28, 2021
Last Verified: April 2021
Additional relevant MeSH terms:
Layout table for MeSH terms